Published in Clinical Oncology Week, August 28th, 2006
Results of the study showed the following:
1) The chemotherapy combination Xeloda plus oxaliplatin, called Xelox, is as effective in terms of progression-free survival - a measure of the time patients live without their disease progressing - as infused 5-fluorouracil/leucovorin plus oxaliplatin, called Folfox;
2) The addition of Avastin to chemotherapy (Folfox and Xelox) significantly improved progression-free survival compared to chemotherapy alone.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week